Remsima is a prescription medication approved by the European Medicines Agency for the treatment of moderate to severe plaque psoriasis in adults who have not responded to or cannot take systemic therapies such as cyclosporine, methotrexate, and psoralen + UVA. Remsima is also indicated for the treatment of active and progressive psoriatic arthritis in cases where response to other disease-modifying anti-rheumatic drugs (DMARDs) has proven inadequate. Remsima may be referred to by its drug name, infliximab.
Remsima is a biologic drug. It is a genetically engineered antibody used by the immune system to identify and neutralize substances. Remsima is believed to work by attaching to tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks. Remsima binds to TNF-α and prevents it from signaling the immune system to attack the connective tissues.
Remsima is a biosimilar of Remicade. As defined by the U.S. Food and Drug Administration, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product.
How do I take it?
Remsima is administered as an intravenous infusion every eight weeks after initial loading doses.
Remsima is available in vial form.
Common side effects of Remsima include upper respiratory tract infections, allergic respiratory symptoms, depression, insomnia, headache, vertigo, dizziness, eye infection, fast heartbeat, changes in blood pressure, infusion-related reactions, and injection site pain.
Rare but serious side effects listed for Remsima can include blood disorders, severe infections, infusion reactions, increased risk for certain types of cancer, and the development of neurological conditions such as multiple sclerosis and Guillain-Barré syndrome.
For more details about this treatment, visit:
Remsima — European Medicines Agency